Navigation Links
Anesiva Announces Second Quarter 2008 Financial Results and Update
Date:8/7/2008

strative 7,914 6,246 16,371 12,000

Total operating expenses 22,102 14,658 43,943 27,374

Loss from operations (21,800) (14,658) (43,640) (27,374)

Interest expense and other income (111) 820 137 1,858

Loss before minority interest (21,911) (13,838) (43,503) (25,516)

Minority interest in loss of

variable interest entity 52 - 61 -

Net loss $(21,859) $(13,838) $(43,442) $(25,516)

Basic and diluted net loss per

common share $(0.54) $(0.51) $(1.08) $(0.93)

Weighted average shares used to

compute basic and diluted net

loss per common share 40,328 27,376 40,299 27,353

Anesiva, Inc.

Condensed Consolidated Balance Sheets

(In thousands)

June 30, December 31,

2008 2007

(Unaudited) (Note)

Assets

Cash and cash equivalents $48,667 $90,840

Other current assets 4,082 2,225

Total current assets 52,749 93,065

Property and equipment, net 17,733 15,276

Other assets, non-current 1,466 1,395

Total assets $71,948 $109,736

Liabilities and stockholders' equity

Current liabilities $15,117 $12,175

Long term obligations 7,882 9,047

Minority interest
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Budding Biomedical Scientists , This ... participated in the Scientific Enrichment and Opportunity ... of Medicine . , The rigorous ... experience in the sciences and brings them in ... students for both academic and career mentoring. , ...
(Date:8/26/2014)... 2014  NeuroSigma, Inc., a Los Angeles ... technologies, today announced that it has filed a registration ... Exchange Commission relating to a proposed initial public offering ... be offered and the price range for the proposed ... LLC will act as the book-running manager for the ...
(Date:8/26/2014)... , Aug. 26, 2014 An analysis ... structures of all Mers CoV virus strains ... structures back to 2012.  This conservation and sharing of ... a Synthetic Mers CoV Blocker-Vaccine™ candidate, as it did for ... vaccine, both of which have been found to be ...
(Date:8/26/2014)... of engineers from Singapore has successfully piloted the ... satellite communications. , With the weight of payloads ... a lightweight, low power-consuming, wireless communication system to ... always been a challenge for system designers. , ... of Nanyang Technological University in Singapore launched VELOX-I, ...
Breaking Biology Technology:Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2ZigBee in the Sky 2
... move aside. Tiny gold stars, smaller than a billionth ... to medical diagnoses or testing for environmental contaminants. , While ... sciences, a new study by Duke University bioengineers indicates that ... above all the rest for certain applications. , The ...
... Stock Exchange Symbol: MS, EDMONTON, Nov. 6 ... developer in the treatment of multiple sclerosis (MS), ... quarter ended,September 30, 2008. BioMS Medical, in partnership ... (MBP8298), a drug for the,treatment of MS undergoing ...
... ... LymphoStat-B(R) Phase 3 trials; first Phase 3 ... in mid-2009 - ... Genome Sciences,Inc. (Nasdaq: HGSI ) today announced financial results and key developments,for the quarter ended September ...
Cached Biology Technology:Gold nanostar shape of the future 2Gold nanostar shape of the future 3BioMS Medical Announces Third Quarter 2008 Results 2BioMS Medical Announces Third Quarter 2008 Results 3BioMS Medical Announces Third Quarter 2008 Results 4BioMS Medical Announces Third Quarter 2008 Results 5Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 2Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 3Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 4Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 5Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 6Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 7Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 8Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 9Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 10
(Date:8/25/2014)... manipulating the behavior of ants emits a cocktail ... its natural target host, but not when infecting ... findings, which suggest that the fungus "knows" its ... mechanisms underlying this phenomenon, according to researchers., "Fungi ... chemicals that affect their environment," noted lead author ...
(Date:8/25/2014)... as a lightning strike on August 12, 2014. Currently ... There are close to 2,000 personnel working on ... fires and a number of large ones. Most of ... about 100 acres. An inversion layer settled over the ... 24, keeping fire activity moderate. As the inversion lifted in ...
(Date:8/25/2014)... 25, 2014  Scribe Labs unveiled its first ... and saw its campaign surpass the $50,000 funding ... kinematic metrics that help an athlete understand how ... their running mechanics. Built with an advanced 9-axis ... most advanced set of running metrics available outside ...
Breaking Biology News(10 mins):Zombie ant fungi 'know' brains of their hosts 2Zombie ant fungi 'know' brains of their hosts 3Happy Camper and July Fire Complexes in California 2runScribe Fitness Wearable Exceeds 200% of Kickstarter Goal in First Week 2
... by the University of Colorado at Boulder and the ... liquid crystals of ultrashort DNA molecules immersed in water, ... the emergence of life on Earth. CU-Boulder ... surprisingly short segments of DNA, lifes molecular carrier of ...
... quack-quack there. Farmers may find phytochemicals to be the ... in the bucket that cashes in on the tug-o-war ... the Texas Agricultural Experiment Station. Thats because applying ... increases disease-preventing phytochemicals, or nutrients, for which consumers may ...
... in remote parts of the UK, southern Scandinavia and ... dissolved organic matter. In this weeks Nature journal (22 ... (University College London) and the US Environmental Protection Agency ... a return to a more natural, pre-industrial state following ...
Cached Biology News:Liquid crystal phases of tiny DNA molecules point up new scenario for first life on Earth 2Liquid crystal phases of tiny DNA molecules point up new scenario for first life on Earth 3Liquid crystal phases of tiny DNA molecules point up new scenario for first life on Earth 4Old McDonald had a phytochemical 2Old McDonald had a phytochemical 3Don't judge a brook by its color -- brown waters are more natural 2
Size & Applications: 100 ul (2 mM). Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.) Storage Temp.: -20C Shelf Life: 6-12 month...
in vitro Translation, Accessory Products...
... Origami host strains are K-12 derivatives ... reductase (trxB) and glutathione reductase (gor) genes, ... the cytoplasm. Studies have shown that expression ... than in another host even though overall ...
Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
Biology Products: